loading...| Preferred Name |
p97 Inhibitor CB-5083 |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118287 |
| CAS_Registry |
1542705-92-9 |
| code |
C118287 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
GDC FDA |
| DEFINITION |
An orally bioavailable inhibitor of valosin-containing protein (VCP) p97, with potential antineoplastic activity. Upon oral administration, CB-5083 specifically binds to and inhibits the activity of p97. This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins. The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and inhibition of cell proliferation in susceptible tumor cells. p97, a type II AAA ATPase, plays a key role in cellular protein homeostasis. Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival. |
| FDA_UNII_Code |
591IV6UL6J |
| FULL_SYN |
p97 Inhibitor CB-5083 CB-5083 |
| Is_Value_For_GDC_Property | |
| label |
p97 Inhibitor CB-5083 |
| Maps_To |
p97 Inhibitor CB-5083 |
| NCI_Drug_Dictionary_ID |
764238 |
| PDQ_Closed_Trial_Search_ID |
764238 |
| PDQ_Open_Trial_Search_ID |
764238 |
| Preferred_Name |
p97 Inhibitor CB-5083 |
| prefixIRI |
Thesaurus:C118287 |
| prefLabel |
p97 Inhibitor CB-5083 |
| Semantic_Type |
Pharmacologic Substance |
| UMLS_CUI |
C3896891 |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||